April 8, 2011
Psychedelic Drug Cuts Brain Blood Flow and Connections
By: Arran Frood
By using psilocybin and other psychedelic compounds as scientific tools, neuroscientists are discovering some fascinating new properties of the human mind. A new brain imaging (fMRI) study by Robin Carhart-Harris at Imperial College London has found that the psychedelic or “mind-manifesting” effects of psilocybin could be due to the drug’s ability to decrease, rather than increase, activity in certain parts of the brain. Could this surprising effect have something to do with the therapeutic effects of psilocybin and other drugs that work on the serotonin system? Time—and research—will tell.
Originally appearing at http://www.newscientist.com/article/dn20358-psychedelic-drug-cuts-brain-blood-flow-and-connections.html.
Psychedelic drug users throughout the ages have described their experiences as mind-expanding. They might be surprised, therefore, to hear that psilocybin – the active ingredient in magic mushrooms – actually decreases blood flow as well as connectivity between important areas of the brain that control perception and cognition.
The same areas can be overactive in people who suffer from depression, making the drug a potential treatment option for the condition.
The study is the first time that psilocybin’s effects have been measured with fMRI, and the first experiment involving a hallucinogenic drug and human participants in the UK for decades.
Robin Carhart-Harris at Imperial College London and colleagues recruited 30 volunteers who agreed to be injected with psilocybin and have their brain scanned using two types of fMRI.
Half of the volunteers had their blood flow measured during the resulting trip; the rest underwent a scan that measured connectivity between different regions of the brain.
Less blood flow was seen in the brain regions known as the thalamus, the posterior cingulate and the medial prefrontal cortex. “Seeing a decrease was surprising. We thought profound experience equalled more activity, but this formula is clearly too simplistic,” says Carhart-Harris. “We didn’t see an increase in any regions,” he says.
Decreases in connectivity were also observed, such as between the hippocampus and the posterior cingulate and medial prefrontal cortex.
“Under psilocybin you see a relative decrease in ‘talk’ between the hippocampus and these cortical hub regions,” says Carhart-Harris. “Changes in function in the posterior cingulate in particular are associated with changes in consciousness.”
Psilocybin has a similar chemical structure to serotonin – a hormone involved in regulating mood – and therefore binds to serotonin receptors on nerve cells in the brain. The drug may have therapeutic potential because the serotonin system in nerves is also a target for existing antidepressants.
A study earlier this year by Charles Grob at the University of California, Los Angeles, showed that people with end-stage cancer had significantly less anxiety and better mood after receiving psilocybin (Archives of General Psychiatry, DOI: 10.1001/archgenpsychiatry.2010.116).
Franz Vollenweider, who works in a similar field at the Psychiatric University Hospital Zurich, Switzerland, says that the immediate effects of psilocybin are not as important for clinical benefit as the longer-term effects. That’s because psilocybin increases the expression of genes and signalling proteins associated with nerve growth and connectivity, he says: “We think that the antidepressant effects of psilocybin may be due to a possible increase of factors that activate long-term neuroplasticity.”
Carhart-Harris presented his work at the Breaking Convention conference at the University of Kent in Canterbury, UK, this week.
Back to MAPS in the Media